Social Determinants of Health, Disease, and Treatment Related Characteristics of Access Clinical Trial Participants
Rafeek A. Yusuf(National Marrow Donor Program), Rachel Cusatis(Medical College of Wisconsin), Eric Ndifon(National Marrow Donor Program), Deborah Mattila(National Marrow Donor Program), Michelle Kuxhausen(National Marrow Donor Program), Thomas Silverman(National Marrow Donor Program), Caitrin Bupp(National Marrow Donor Program), Jeffery J. Auletta(Nationwide Children's Hospital), Lindsay Bankole(National Marrow Donor Program), Steven M. Devine(National Marrow Donor Program), Janelle A. Olson(National Marrow Donor Program), Bronwen E. Shaw(Royal Marsden NHS Foundation Trust)
Cited by 1
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441